Development of prophylactic vaccines for genital and neonatal herpes

Expert Review of Vaccines

Volumn 2, Issue 4, 2003, Pages 541-549

  Jones, Cheryl A ^b,c   Cunningham, Anthony L ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Animal models; Clinical trials; Genital herpes vaccine; Herpes simplex virus; Prophylaxis

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GLYCOPROTEIN D; HERPES VACCINE; HERPEVAC; IMMUNOLOGICAL ADJUVANT; LIPID A DERIVATIVE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; R 7017; R 7020; RAV 9395; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SYNTHESIS; GENITAL HERPES; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NEWBORN; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINES, DNA; VACCINES, SUBUNIT; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0041733075     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.4.541     Document Type: Review

References (63)

1. Cunningham AL, Mindel AL, Dwyer DE. Global epidemiology of sexually transmitted diseases. In: Sexually Transmitted Diseases: Vaccines, Prevention and Control. Stanberry LR, Bernstein DI (Eds). Academic Press, London, UK, 3-42 (2001).
2. Stanberry LR, Cunningham AL, Mindel A et al. Prospects for control of herpes simplex virus disease through immunization. Clin. Inject Dis. 30, 549-566 (2000).
3. Corey L, Tyring S, Beutner K et al. Once daily valaciclovir reduces transmission of genital herpes. Abstract LB-3, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA, September 2002.
4. Mindel A, Taylor J. Debate: the argument against. Should every STD attendee be considered for type specific serologic screening. Herpes 9, 32-34 (2002).
5. Cunningham AL, Mikloska ZM. The holy grail: immune control of human herpes simplex virus infection and disease. Herpes 8, 1 (2001).
6. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16, 96-113 (2003).
7. Whitely RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J. Clin. Invest. 110(2), 145-151 (2002).
8. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661 (2002).
9. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Topics Microbiol. Immun. 179, 137-158 (1992).
10. Vandepapalier P. Therapeutic vaccination against chronic viral infections. Lancet Infect. Dis. 2(6), 353-367 (2002).
11. Sedarati F, Javier RT, Stevens JG. Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains. J. Virology 62, 3037-3039 (1988).
12. Roizman B, Warren J, Thuning CA, Fanshaw MS, Norrild B, Meignier B. Application of molecular genetics to the design of live herpes simplex virus vaccines. Develop. Biol. Standardization 52, 287-304 (1982).
13. Meignier B, Roizman B. Herpes simplex virus vaccines. Antiviral Res. 1, 259-265 (1985).
14. Meignier B, Longnecker R, Roizman B. In vivo behaviour of genetically engineered herpes simplex viruses R7017 and R 7020: construction and evaluation in rodents. J. Infect Dis. 158, 602-614 (1988).
15. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313-321 (1990).
16. Thompson RL, Nakashizuka M, Stevens JG. Vaccine potential of a live avirulent herpes simplex virus. Microb. Pathog. 1, 409-416 (1986).
17. Irie H, Haraday, Kataoka M et al. Efficacy of oral administration of live herpes simplex virus Type 1 as a vaccine. J. Virology 66, 2428-2434 (1992).
18. Walz MA, Price RW, Hayashi K, Katz BJ, Notkins AL. Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2. J. Infect Dis. 135, 744-752 (1977).
19. Mercadal CM, Slaoui M, Brown SM, Rouse BT. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice. Viral Immunol. 6, 35-42 (1993).
20. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus Type 1: sites of immune intervention in pathogenesis of challenge of virus infection. J. Virology 68, 689-4596 (1994).
21. Spector FC, Kern ER, Palmer J et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus Type 2 vaccine in guinea-pigs. J. Infect. Dis. 177, 1143-1154 (1998).
22. Walker J, Leib D. Protection from primary infection and establishment of latency by vaccination with a herpes simplex Type 1 recombinant deficient in the virion host shutoff (VHS). Vaccine 16, 1-5 (1998).
23. Geiss BJ, Smith TJ, Leib DA, Morrison LA. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus Type 1 vaccine strain. J. Virol 74, 11137-11144 (2000).
24. Jacobson JG, Leib DA, Goldstein DJ et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173(1), 276-283 (1989).
25. Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus Type 2 mutant deleted in the PK domain of the large subunit of ribonudeotide reductase (ICP10). Vaccine 17, 1951-1963 (1999).
26. + cytotoxic T-lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10δPK. Vaccine 20(21-22), 2796-2807 (2002).
27. Casanova G, Cancela R, Alonzo L et al. A double-blind study of the efficacy and safety of the ICP10δPK vaccine against recurrent genital HSV-2 infections. Cutis 70(4), 205-206 (2002).
28. + T-lymphocytes. J. Immunol. 155, 259-265 (1995).
29. Fleck M, Podlech J, Weise K, Falke D. A vaccinia virus herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV Type 2 induced humoral immunosuppression and protect against vaginal challenge in balb/C mice. Med Microbiol. Immunol. 183, 87-94 (1994).
30. Aurelian L, Smith CC, Wachsman M, Paoletti E. Immune responses to herpes simplex virus in guinea-pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Revs Infect. Dis. 13, 924-934 (1991).
31. Allen EM, Weir JP, Martin S, Mercadal C, Rouse BT. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity. Viral Immunol. 3, 207-201 (1990).
32. McDermott MR, Graham FL, Hanke T, Johnson DC. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B. Virology 169, 244-247 (1989).
33. Gallichan WS, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.J. Infect. Dis. 168, 622-629 (1993).
34. Heineman TC, Cohen JI. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J. Virology 69, 7367-7370 (1995).
35. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 18, 1351-1358 (2000).
36. Blacklaws BA, Krishna S, Minson AC, Nash AA. Immunogenecity of herpes simplex virus Type 1 glycoproteins expressed in vaccinia virus recombinants. Virology 177, 727-736 (1990).
37. Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, McLean AC. Vaccine potential of a herpes simplex virus Type 1 mutant with an essential glycoprotein deleted. J. Virology 68, 927-932 (1994).
38. McLean CS, Erturk M, Jennings R et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) Type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170, 1100-1109 (1994).
39. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J. Virol. 74, 7963-7967 (2000).
40. Morrison LA, Knipe DM. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology 70, 402-413 (1996).
41. Morrison LA, Knipe DM. Contributions of antibody and T-cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus Type 1. Virology 239, 315-326 (1997).
42. Da Costa XJ, Bourne N, Stanberry LR Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea-pig model of genital disease. Virology 232, 1-12 (1997).
43. DCosta XDC, Jones CA, Knipe DK. Immunization against genital herpes with a vaccine virus defective for productive and latent infection. Proc. Natl Acad Sci. USA 96, 6994 (1999).
44. Evans IE, Jones CA. Protection against disseminated neonatal HSV disease by maternal immunisation with an HSV-2 replication-defective mutant in mice. J. Infect. Dis. 185, 1550 (2002).
45. Skinner GR, Woodman CB, Hartley CE, Buchan A, Fuller A, Durham J et al. Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis. Br. J. Vener. Dis. 58, 381-386 (1982).
46. Skinner GR, Woodman C, Hartley C et al. Early experience with 'antigenoid' vaccine Ac NFU1 (S-) MRC towards prevention or modification of herpes genitalis. Dev. Biol. Stand 52, 333-344 (1982).
47. Skinner GR, Fink CG, Cowan M et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med. Microbiol. Immunol. 176, 161-168 (1987).
48. Kriesel JD, Spruance SL, Daynes RA, Araneo BA. Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus Type 2 disease. J. Infect. Dis. 173, 536-541 (1996).
49. Bourne N, Milligan GN, Scleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex Type 2. Vaccine 14, 1230-1234 (1996).
50. Bourne N, Stanberry L, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173, 800-807 (1996).
51. McClements WL, Armstrong M, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc. Natl Acad. Sci. 93, 11414-11420 (1996).
52. McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease. Vaccine 15, 857-860 (1997).
53. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451-3457 (2001).
54. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 19, 4685-4693 (2001).
55. Eo SK, Gierynska M, Kamar AA, Rouse BT. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166, 5473-5479 (2001).
56. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155, 914-920 (1987).
57. Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent and latent genital infections with herpes simplex virus Type 2 in guinea-pigs. J. Infect. Dis. 157, 897-902 (1988).
58. Cappel R, Sprecher S, de Cuyper F, de Braekeleer J. Clinical efficacy of a herpes simplex subunit vaccine. J. Med Virol. 16, 137-145 (1985).
59. Mertz GJ, Ashley R, Burke RL et al. Double-blind, placebo-controlled trial of a herpes simplex virus Type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161, 653-660 (1990).
60. Straus SE, Corey L, Burke RL. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus Type 2 for immunotherapy of genital herpes. Lancet 343(8911), 1460-1463 (1994).
61. Stanberry L, Spruance S, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661 (2002).
62. Blaney JE Jr, Nobusawa E, Brehm MA, Bonneau RH, Mylin LM, Fu TM. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus Type 2 confers protective immunity. J. Virol. 72, 9567-9574 (1998).
63. Thompson SJ, Francis JN, Siew LK et al. An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. J. Immunol. 160(9), 4628-4634 (1998).